格隆汇12月17日丨力生制药(002393.SZ)公布，近日，公司收到郭晓燕女士出具的《关于股份减持计划 实施完成的告知函》，公司副总经理郭晓燕女士于2025年12月16日-2025年12月17日以集中竞价交易的 方式合计减持本公司股份数量1.12万股，占公司剔除回购专用账户中股份数量后总股本的0.0044%。 ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 天津力生制药股份有限公司（以下简称"公司"）于2025年11月21日在《中国证券报》 《证券时报》和巨潮资讯网（www.cninfo.com.cn）上披露了《关于公司高级管理人员减持 股份预披露公告》（公告编号：2025-075），公司副总经理郭晓燕女士拟自减持计划公告 之日起15个交易日后的3个月内以集中竞价交易的方式合计减持本公司股份数量不超过 11,200股，拟减持股份比例不超过公司剔除回购专用账户中股份数量后总股本的0.0044%。 近日，公司收到郭晓燕女士出具的《关于股份减持计划实施完成的告知函》，现将有 关减持计划实施完成情况公告如下： 证券代码：002393 证券简称：力生制药 公告编号：2025-086 天津力生制药股份有限公司 关于公司高级管理人员减持计划实施完成的公告 本公司高级管理人员郭晓燕女士保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 1、本次减持计划实施符合《中华人民共和国证券法》《上市公司股东减持股份管理暂 行办法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规 ...

力生制药公告称，副总经理郭晓燕于2025年11月21日披露减持计划，拟在15个交易日后的3个月内，以 集中竞价方式减持不超11,200股，占公司剔除回购专用账户中股份数量后总股本的0.0044%。近日，减 持计划实施完成，郭晓燕于12月16 - 17日减持11,200股，减持均价19.90元/股，占比0.0044%。减持后， 其持有无限售条件股份为0股，限售股份103,600股，合计持股占比降至0.0404%。本次减持未超计划， 不影响公司控制权和持续经营。 ...

董事会薪酬与考核委员会关于2024年限制性股票激励 计划预留部分授予激励对象名单公示情况的说明及核查 意见 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《公司法》《证券法》《深圳证券交易所股票上市规则》《上市公司股权激励管 理办法》（以下简称《管理办法》）《中央企业控股上市公司实施股权激励工作指引》（以 下简称《实施指引》）等相关法律、法规以及《公司章程》的有关规定，天津力生制药股 份有限公司（以下简称"公司"）对公司2024年限制性股票激励计划拟授予预留部分限 制性股票的激励对象名单在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示 情况对激励对象名单进行了核查，相关公示情况及核查意见如下： 证券代码：002393 证券简称：力生制药 公告编号：2025-085 天津力生制药股份有限公司 一、公示情况 公司于2025年12月5日至2025年12月15日在公司内部对激励对象的姓名和职务予以 公示，人数为22人。公示期内，没有任何组织或个人对激励对象名单提出任何异议。 董事会 2025 年 12 月 16 日 2.激励对象具备《公司法》等法律法规、 ...

Core Viewpoint - Recently, the company announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., received drug registration certificates for Apremilast tablets in three different specifications: 10mg, 20mg, and 30mg, indicating successful approval for market entry [2]. Group 1 - The company has obtained the drug registration certificate for Apremilast tablets 10mg (Approval No. 2025S03538) [2] - The company has also received the drug registration certificate for Apremilast tablets 20mg (Approval No. 2025S03539) [2] - Additionally, the company secured the drug registration certificate for Apremilast tablets 30mg (Approval No. 2025S03540) [2]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in three dosages: 10mg, 20mg, and 30mg, indicating successful approval for market entry [1] Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1] - The registration certificates have the following batch numbers: 2025S03538 for 10mg, 2025S03539 for 20mg, and 2025S03540 for 30mg [1]

| 药品名称 | | 阿普米司特片 | | | | --- | --- | --- | --- | --- | | 剂 | 型 | 片 剂 | | | | 规 | 格 | 10mg | 20mg | 30mg | | 注册分类 | | 化学药品4类 | | | | 药品生产企业 | | 天津市中央药业有限公司 | | | | 原药品批准文号 | | 无 | | | | 申请内容 | | 上市许可申请 | | | | 受理号 | | CYHS2401628 | CYHS2401629 | CYHS2401630 | | 审批结论 | | 通过上市许可申请 | | | 三、该药品的相关信息 阿普米司特片适应症为：本品用于治疗符合接受光疗或系统治疗指征的中度至重度斑块 状银屑病的成人患者。 证券代码：002393 证券简称：力生制药 公告编号：2025-084 天津力生制药股份有限公司 关于子公司中央药业药品阿普米司特片 通过上市许可申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"公司"或"本公司"）的 ...

Core Viewpoint - Company Tianjin Central Pharmaceutical Co., Ltd., a subsidiary of Lisheng Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, indicating successful approval for market access [1] Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1]

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, indicating successful approval for market entry [1]. Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1].